Anticoagulant Reversal Drugs Market Size, Share & Trends Analysis Report By Product Type (Andexanet Alfa, Idarucizumab, Phytonadione (Vitamin K)), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

Anticoagulant Reversal Drugs Market Size, Share & Trends Analysis Report By Product Type (Andexanet Alfa, Idarucizumab, Phytonadione (Vitamin K)), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030


Bio-based Polyurethane Market Growth & Trends

The global bio-based polyurethane market size is estimated to reach USD 64,596.15 thousand by 2030, registering a CAGR of 8.99% from 2025 to 2030, according to a new report by Grand View Research, Inc. Growing awareness among consumers, environmental concerns, and stringent government regulations are contributing to the increased use of bio-based plastics and in turn, driving the growth of the bio-based polyurethane industry.

Bio-based polyurethane is bio-sourced and breaks down faster as compared to petroleum-based plastics. Due to their decreased carbon footprint, they remain a preferred option over traditional plastics. The rising emphasis on sustainable products is a key factor driving the growth of the packaging industry, which is expected to result in reduced consumption of petroleum-based products and a shift toward bio-based alternatives.

Moreover, bio-based polyurethane is increasingly being used to manufacture single-use packaging materials that include shopping bags and disposable cutlery, which is likely to boost their demand over the forecast period. Bio-based polyurethane is an environmentally friendly alternative to traditional plastics, notably in flexible and rigid packaging applications, as they are bio-based, compostable, and biodegradable.

Bio-based polyurethane is widely used in automotive applications such as seat cushions, seat backs, armrests, head restraints, and others. Increasing environmental concerns and the inclination of consumers toward sustainable products are pushing automotive manufacturers toward the adoption of bio-based polyurethane in automotive applications. For instance, Ford Motor Company, one of the leading global automobile manufacturers, is using bio-based polyurethane in the above-mentioned automobile applications.

Bio-based Polyurethane Market Report Highlights
  • Asia Pacific accounted for the largest regional share of over 38.37% in 2024 in terms of revenue. Asia Pacific market is likely to grow owing to the rising demand for the product from key industries including car and transportation, electronics, textile, packaging, appliance, and medical
  • Flexible foams dominated the end-use segment in the market, accounting for over 50.61% share in terms of revenue, due to its several uses in automotive, furniture & mattress, footwear, textile, handbag & luggage, home appliances, and packaging end-use among others
  • Building & construction dominated the end-use segment in the market accounting for over 33.67% in terms of revenue. Growing urbanization and industrialization, especially in emerging economies, such as China and India, coupled with growing infrastructure development activities is expected to boost the bio-based polyurethane in the building & construction industry in the coming years
  • In March 2023, Mitsui Chemicals, Inc. announced intentions to enhance the toluene diisocyanate (TDI) manufacturing capacity of its Omuta Works plant in July 2025. TDI is a raw ingredient used in the manufacturing of bio-based polyurethane.
Please note The report will be delivered in 2-3 business days upon order notification.


Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product Type
1.2.2. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Anticoagulant Reversal Drugs Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
Chapter 4. Anticoagulant Reversal Drugs Market: Product Type Business Analysis
4.1. Product Type Market Share, 2024 & 2030
4.2. Product Type Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Product Type, 2018 to 2030 (USD Million)
4.4. Prothrombin Complex Concentrates
4.4.1. Prothrombin Complex Concentrates Market, 2018 - 2030 (USD Million)
4.5. Phytonadione (Vitamin K)
4.5.1. Phytonadione (Vitamin K) Market, 2018 - 2030 (USD Million)
4.6. Andexanet Alfa
4.6.1. Andexanet Alfa Market, 2018 - 2030 (USD Million)
4.7. Idarucizumab
4.7.1. Idarucizumab Market, 2018 - 2030 (USD Million)
4.8. Protamine
4.8.1. Protamine Market, 2018 - 2030 (USD Million)
4.9. Others
4.9.1. Others Market, 2018 - 2030 (USD Million)
Chapter 5. Anticoagulant Reversal Drugs Market: Distribution Channel Business Analysis
5.1. Distribution Channel Market Share, 2024 & 2030
5.2. Distribution Channel Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
5.4. Hospital Pharmacy
5.4.1. Hospital Pharmacy Market, 2018 - 2030 (USD Million)
5.5. Retail Pharmacy
5.5.1. Retail Pharmacy Market, 2018 - 2030 (USD Million)
5.6. Online Pharmacy
5.6.1. Online Pharmacy Market, 2018 - 2030 (USD Million)
Chapter 6. Anticoagulant Reversal Drugs Market: Regional Estimates & Trend Analysis by Product Type
6.1. Regional Market Share Analysis, 2024 & 2030
6.2. Regional Market Dashboard
6.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
6.4. North America
6.4.1. North America Anticoagulant Reversal Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Million)
6.4.2. U.S.
6.4.2.1. Key Country Dynamics
6.4.2.2. Regulatory Framework
6.4.2.3. Competitive Insights
6.4.2.4. U.S. Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.3. Canada
6.4.3.1. Key Country Dynamics
6.4.3.2. Regulatory Framework
6.4.3.3. Competitive Insights
6.4.3.4. Canada Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.4. Mexico
6.4.4.1. Key Country Dynamics
6.4.4.2. Regulatory Framework
6.4.4.3. Competitive Insights
6.4.4.4. Mexico Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Europe
6.5.1. Europe Anticoagulant Reversal Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Million)
6.5.2. UK
6.5.2.1. Key Country Dynamics
6.5.2.2. Regulatory Framework
6.5.2.3. Competitive Insights
6.5.2.4. UK Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.3. Germany
6.5.3.1. Key Country Dynamics
6.5.3.2. Regulatory Framework
6.5.3.3. Competitive Insights
6.5.3.4. Germany Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.4. France
6.5.4.1. Key Country Dynamics
6.5.4.2. Regulatory Framework
6.5.4.3. Competitive Insights
6.5.4.4. France Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.5. Italy
6.5.5.1. Key Country Dynamics
6.5.5.2. Regulatory Framework
6.5.5.3. Competitive Insights
6.5.5.4. Italy Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.6. Spain
6.5.6.1. Key Country Dynamics
6.5.6.2. Regulatory Framework
6.5.6.3. Competitive Insights
6.5.6.4. Spain Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.7. Norway
6.5.7.1. Key Country Dynamics
6.5.7.2. Regulatory Framework
6.5.7.3. Competitive Insights
6.5.7.4. Norway Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.8. Denmark
6.5.8.1. Key Country Dynamics
6.5.8.2. Regulatory Framework
6.5.8.3. Competitive Insights
6.5.8.4. Denmark Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.9. Sweden
6.5.9.1. Key Country Dynamics
6.5.9.2. Regulatory Framework
6.5.9.3. Competitive Insights
6.5.9.4. Sweden Anticoagulant Reversal Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Million)
6.6. Asia Pacific
6.6.1. Asia Pacific Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.2. Japan
6.6.2.1. Key Country Dynamics
6.6.2.2. Regulatory Framework
6.6.2.3. Competitive Insights
6.6.2.4. Japan Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.3. China
6.6.3.1. Key Country Dynamics
6.6.3.2. Regulatory Framework
6.6.3.3. Competitive Insights
6.6.3.4. China Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.4. India
6.6.4.1. Key Country Dynamics
6.6.4.2. Regulatory Framework
6.6.4.3. Competitive Insights
6.6.4.4. India Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.5. South Korea
6.6.5.1. Key Country Dynamics
6.6.5.2. Regulatory Framework
6.6.5.3. Competitive Insights
6.6.5.4. South Korea Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.6. Australia
6.6.6.1. Key Country Dynamics
6.6.6.2. Regulatory Framework
6.6.6.3. Competitive Insights
6.6.6.4. Australia Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.7. Thailand
6.6.7.1. Key Country Dynamics
6.6.7.2. Regulatory Framework
6.6.7.3. Competitive Insights
6.6.7.4. Thailand Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7. Latin America
6.7.1. Latin America Anticoagulant Reversal Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Million)
6.7.2. Brazil
6.7.2.1. Key Country Dynamics
6.7.2.2. Regulatory Framework
6.7.2.3. Competitive Insights
6.7.2.4. Brazil Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7.3. Argentina
6.7.3.1. Key Country Dynamics
6.7.3.2. Regulatory Framework
6.7.3.3. Competitive Insights
6.7.3.4. Argentina Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8. MEA
6.8.1. MEA Anticoagulant Reversal Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Million)
6.8.2. South Africa
6.8.2.1. Key Country Dynamics
6.8.2.2. Regulatory Framework
6.8.2.3. Competitive Insights
6.8.2.4. South Africa Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8.3. Saudi Arabia
6.8.3.1. Key Country Dynamics
6.8.3.2. Regulatory Framework
6.8.3.3. Competitive Insights
6.8.3.4. Saudi Arabia Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8.4. UAE
6.8.4.1. Key Country Dynamics
6.8.4.2. Regulatory Framework
6.8.4.3. Competitive Insights
6.8.4.4. UAE Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8.5. Kuwait
6.8.5.1. Key Country Dynamics
6.8.5.2. Regulatory Framework
6.8.5.3. Competitive Insights
6.8.5.4. Kuwait Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Anticoagulant Reversal Drugs Market: Regional Estimates & Trend Analysis by Distribution Channel
7.1. Regional Market Share Analysis, 2024 & 2030
7.2. Regional Market Dashboard
7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.4. North America
7.4.1. North America Anticoagulant Reversal Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Million)
7.4.2. U.S.
7.4.2.1. Key Country Dynamics
7.4.2.2. Regulatory Framework
7.4.2.3. Competitive Insights
7.4.2.4. U.S. Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.3. Canada
7.4.3.1. Key Country Dynamics
7.4.3.2. Regulatory Framework
7.4.3.3. Competitive Insights
7.4.3.4. Canada Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.4. Mexico
7.4.4.1. Key Country Dynamics
7.4.4.2. Regulatory Framework
7.4.4.3. Competitive Insights
7.4.4.4. Mexico Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Europe
7.5.1. Europe Anticoagulant Reversal Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Million)
7.5.2. UK
7.5.2.1. Key Country Dynamics
7.5.2.2. Regulatory Framework
7.5.2.3. Competitive Insights
7.5.2.4. UK Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.3. Germany
7.5.3.1. Key Country Dynamics
7.5.3.2. Regulatory Framework
7.5.3.3. Competitive Insights
7.5.3.4. Germany Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.4. France
7.5.4.1. Key Country Dynamics
7.5.4.2. Regulatory Framework
7.5.4.3. Competitive Insights
7.5.4.4. France Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.5. Italy
7.5.5.1. Key Country Dynamics
7.5.5.2. Regulatory Framework
7.5.5.3. Competitive Insights
7.5.5.4. Italy Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.6. Spain
7.5.6.1. Key Country Dynamics
7.5.6.2. Regulatory Framework
7.5.6.3. Competitive Insights
7.5.6.4. Spain Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.7. Norway
7.5.7.1. Key Country Dynamics
7.5.7.2. Regulatory Framework
7.5.7.3. Competitive Insights
7.5.7.4. Norway Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.8. Denmark
7.5.8.1. Key Country Dynamics
7.5.8.2. Regulatory Framework
7.5.8.3. Competitive Insights
7.5.8.4. Denmark Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.9. Sweden
7.5.9.1. Key Country Dynamics
7.5.9.2. Regulatory Framework
7.5.9.3. Competitive Insights
7.5.9.4. Sweden Anticoagulant Reversal Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Million)
7.6. Asia Pacific
7.6.1. Asia Pacific Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.2. Japan
7.6.2.1. Key Country Dynamics
7.6.2.2. Regulatory Framework
7.6.2.3. Competitive Insights
7.6.2.4. Japan Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.3. China
7.6.3.1. Key Country Dynamics
7.6.3.2. Regulatory Framework
7.6.3.3. Competitive Insights
7.6.3.4. China Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.4. India
7.6.4.1. Key Country Dynamics
7.6.4.2. Regulatory Framework
7.6.4.3. Competitive Insights
7.6.4.4. India Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.5. South Korea
7.6.5.1. Key Country Dynamics
7.6.5.2. Regulatory Framework
7.6.5.3. Competitive Insights
7.6.5.4. South Korea Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.6. Australia
7.6.6.1. Key Country Dynamics
7.6.6.2. Regulatory Framework
7.6.6.3. Competitive Insights
7.6.6.4. Australia Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.7. Thailand
7.6.7.1. Key Country Dynamics
7.6.7.2. Regulatory Framework
7.6.7.3. Competitive Insights
7.6.7.4. Thailand Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.7. Latin America
7.7.1. Latin America Anticoagulant Reversal Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Million)
7.7.2. Brazil
7.7.2.1. Key Country Dynamics
7.7.2.2. Regulatory Framework
7.7.2.3. Competitive Insights
7.7.2.4. Brazil Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.7.3. Argentina
7.7.3.1. Key Country Dynamics
7.7.3.2. Regulatory Framework
7.7.3.3. Competitive Insights
7.7.3.4. Argentina Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.8. MEA
7.8.1. MEA Anticoagulant Reversal Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Million)
7.8.2. South Africa
7.8.2.1. Key Country Dynamics
7.8.2.2. Regulatory Framework
7.8.2.3. Competitive Insights
7.8.2.4. South Africa Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.8.3. Saudi Arabia
7.8.3.1. Key Country Dynamics
7.8.3.2. Regulatory Framework
7.8.3.3. Competitive Insights
7.8.3.4. Saudi Arabia Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.8.4. UAE
7.8.4.1. Key Country Dynamics
7.8.4.2. Regulatory Framework
7.8.4.3. Competitive Insights
7.8.4.4. UAE Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.8.5. Kuwait
7.8.5.1. Key Country Dynamics
7.8.5.2. Regulatory Framework
7.8.5.3. Competitive Insights
7.8.5.4. Kuwait Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Participant Overview
8.2. Company Market Position Analysis
8.3. Company Categorization
8.4. Strategy Mapping
8.5. Company Profiles/Listing
8.5.1. Pfizer Inc
8.5.1.1. Overview
8.5.1.2. Financial Performance
8.5.1.3. Product Benchmarking
8.5.1.4. Strategic Initiatives
8.5.2. AstraZeneca
8.5.2.1. Overview
8.5.2.2. Financial Performance
8.5.2.3. Product Benchmarking
8.5.2.4. Strategic Initiatives
8.5.3. Dr. Reddy’s Laboratories Ltd
8.5.3.1. Overview
8.5.3.2. Financial Performance
8.5.3.3. Product Benchmarking
8.5.3.4. Strategic Initiatives
8.5.4. Endo International plc
8.5.4.1. Overview
8.5.4.2. Financial Performance
8.5.4.3. Product Benchmarking
8.5.4.4. Strategic Initiatives
8.5.5. Teva Pharmaceutical Industries Ltd
8.5.5.1. Overview
8.5.5.2. Financial Performance
8.5.5.3. Product Benchmarking
8.5.5.4. Strategic Initiatives
8.5.6. Sun Pharmaceutical Industries Ltd
8.5.6.1. Overview
8.5.6.2. Financial Performance
8.5.6.3. Product Benchmarking
8.5.6.4. Strategic Initiatives
8.5.7. Mylan N.V.
8.5.7.1. Overview
8.5.7.2. Financial Performance
8.5.7.3. Product Benchmarking
8.5.7.4. Strategic Initiatives
8.5.8. Novartis AG.
8.5.8.1. Overview
8.5.8.2. Financial Performance
8.5.8.3. Product Benchmarking
8.5.8.4. Strategic Initiatives
8.5.9. Lupin
8.5.9.1. Overview
8.5.9.2. Financial Performance
8.5.9.3. Product Benchmarking
8.5.9.4. Strategic Initiatives
8.5.10. Cipla Inc
8.5.10.1. Overview
8.5.10.2. Financial Performance
8.5.10.3. Product Benchmarking
8.5.10.4. Strategic Initiatives

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings